246 related articles for article (PubMed ID: 27639545)
1. In vivo proof-of-concept of removal of the huntingtin caspase cleavage motif-encoding exon 12 approach in the YAC128 mouse model of Huntington's disease.
Casaca-Carreira J; Toonen LJA; Evers MM; Jahanshahi A; van-Roon-Mom WMC; Temel Y
Biomed Pharmacother; 2016 Dec; 84():93-96. PubMed ID: 27639545
[TBL] [Abstract][Full Text] [Related]
2. Preventing formation of toxic N-terminal huntingtin fragments through antisense oligonucleotide-mediated protein modification.
Evers MM; Tran HD; Zalachoras I; Meijer OC; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; van Roon-Mom WM
Nucleic Acid Ther; 2014 Feb; 24(1):4-12. PubMed ID: 24380395
[TBL] [Abstract][Full Text] [Related]
3. Alternative processing of human HTT mRNA with implications for Huntington's disease therapeutics.
Fienko S; Landles C; Sathasivam K; McAteer SJ; Milton RE; Osborne GF; Smith EJ; Jones ST; Bondulich MK; Danby ECE; Phillips J; Taxy BA; Kordasiewicz HB; Bates GP
Brain; 2022 Dec; 145(12):4409-4424. PubMed ID: 35793238
[TBL] [Abstract][Full Text] [Related]
4. Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease.
Wellington CL; Ellerby LM; Gutekunst CA; Rogers D; Warby S; Graham RK; Loubser O; van Raamsdonk J; Singaraja R; Yang YZ; Gafni J; Bredesen D; Hersch SM; Leavitt BR; Roy S; Nicholson DW; Hayden MR
J Neurosci; 2002 Sep; 22(18):7862-72. PubMed ID: 12223539
[TBL] [Abstract][Full Text] [Related]
5. Lowering Mutant Huntingtin Using Tricyclo-DNA Antisense Oligonucleotides As a Therapeutic Approach for Huntington's Disease.
Imbert M; Blandel F; Leumann C; Garcia L; Goyenvalle A
Nucleic Acid Ther; 2019 Oct; 29(5):256-265. PubMed ID: 31184975
[TBL] [Abstract][Full Text] [Related]
6. Does the Mutant CAG Expansion in Huntingtin mRNA Interfere with Exonucleolytic Cleavage of its First Exon?
Liu W; Pfister EL; Kennington LA; Chase KO; Mueller C; DiFiglia M; Aronin N
J Huntingtons Dis; 2016; 5(1):33-8. PubMed ID: 27003665
[TBL] [Abstract][Full Text] [Related]
7. Phenotype onset in Huntington's disease knock-in mice is correlated with the incomplete splicing of the mutant huntingtin gene.
Franich NR; Hickey MA; Zhu C; Osborne GF; Ali N; Chu T; Bove NH; Lemesre V; Lerner RP; Zeitlin SO; Howland D; Neueder A; Landles C; Bates GP; Chesselet MF
J Neurosci Res; 2019 Dec; 97(12):1590-1605. PubMed ID: 31282030
[TBL] [Abstract][Full Text] [Related]
8. Antisense oligonucleotide-mediated correction of transcriptional dysregulation is correlated with behavioral benefits in the YAC128 mouse model of Huntington's disease.
Stanek LM; Yang W; Angus S; Sardi PS; Hayden MR; Hung GH; Bennett CF; Cheng SH; Shihabuddin LS
J Huntingtons Dis; 2013; 2(2):217-28. PubMed ID: 25063516
[TBL] [Abstract][Full Text] [Related]
9. Caspase 3-cleaved N-terminal fragments of wild-type and mutant huntingtin are present in normal and Huntington's disease brains, associate with membranes, and undergo calpain-dependent proteolysis.
Kim YJ; Yi Y; Sapp E; Wang Y; Cuiffo B; Kegel KB; Qin ZH; Aronin N; DiFiglia M
Proc Natl Acad Sci U S A; 2001 Oct; 98(22):12784-9. PubMed ID: 11675509
[TBL] [Abstract][Full Text] [Related]
10. Elimination of huntingtin in the adult mouse leads to progressive behavioral deficits, bilateral thalamic calcification, and altered brain iron homeostasis.
Dietrich P; Johnson IM; Alli S; Dragatsis I
PLoS Genet; 2017 Jul; 13(7):e1006846. PubMed ID: 28715425
[TBL] [Abstract][Full Text] [Related]
11. Targeting CAG repeat RNAs reduces Huntington's disease phenotype independently of huntingtin levels.
Rué L; Bañez-Coronel M; Creus-Muncunill J; Giralt A; Alcalá-Vida R; Mentxaka G; Kagerbauer B; Zomeño-Abellán MT; Aranda Z; Venturi V; Pérez-Navarro E; Estivill X; Martí E
J Clin Invest; 2016 Nov; 126(11):4319-4330. PubMed ID: 27721240
[TBL] [Abstract][Full Text] [Related]
12. A novel humanized mouse model of Huntington disease for preclinical development of therapeutics targeting mutant huntingtin alleles.
Southwell AL; Skotte NH; Villanueva EB; Østergaard ME; Gu X; Kordasiewicz HB; Kay C; Cheung D; Xie Y; Waltl S; Dal Cengio L; Findlay-Black H; Doty CN; Petoukhov E; Iworima D; Slama R; Ooi J; Pouladi MA; Yang XW; Swayze EE; Seth PP; Hayden MR
Hum Mol Genet; 2017 Mar; 26(6):1115-1132. PubMed ID: 28104789
[TBL] [Abstract][Full Text] [Related]
13. Caspases in Huntington's disease.
Sanchez Mejia RO; Friedlander RM
Neuroscientist; 2001 Dec; 7(6):480-9. PubMed ID: 11765125
[TBL] [Abstract][Full Text] [Related]
14. The dynamics of early-state transcriptional changes and aggregate formation in a Huntington's disease cell model.
van Hagen M; Piebes DGE; de Leeuw WC; Vuist IM; van Roon-Mom WMC; Moerland PD; Verschure PJ
BMC Genomics; 2017 May; 18(1):373. PubMed ID: 28499347
[TBL] [Abstract][Full Text] [Related]
15. Astrocyte transduction is required for rescue of behavioral phenotypes in the YAC128 mouse model with AAV-RNAi mediated HTT lowering therapeutics.
Stanek LM; Bu J; Shihabuddin LS
Neurobiol Dis; 2019 Sep; 129():29-37. PubMed ID: 31042572
[TBL] [Abstract][Full Text] [Related]
16. Enhanced immune response to MMP3 stimulation in microglia expressing mutant huntingtin.
Connolly C; Magnusson-Lind A; Lu G; Wagner PK; Southwell AL; Hayden MR; Björkqvist M; Leavitt BR
Neuroscience; 2016 Jun; 325():74-88. PubMed ID: 27033979
[TBL] [Abstract][Full Text] [Related]
17. Atypical ubiquitination by E3 ligase WWP1 inhibits the proteasome-mediated degradation of mutant huntingtin.
Lin L; Jin Z; Tan H; Xu Q; Peng T; Li H
Brain Res; 2016 Jul; 1643():103-12. PubMed ID: 27107943
[TBL] [Abstract][Full Text] [Related]
18. Protection by dietary restriction in the YAC128 mouse model of Huntington's disease: Relation to genes regulating histone acetylation and HTT.
Moreno CL; Ehrlich ME; Mobbs CV
Neurobiol Dis; 2016 Jan; 85():25-34. PubMed ID: 26485309
[TBL] [Abstract][Full Text] [Related]
19. Increased caspase-2, calpain activations and decreased mitochondrial complex II activity in cells expressing exogenous huntingtin exon 1 containing CAG repeat in the pathogenic range.
Majumder P; Raychaudhuri S; Chattopadhyay B; Bhattacharyya NP
Cell Mol Neurobiol; 2007 Dec; 27(8):1127-45. PubMed ID: 17902043
[TBL] [Abstract][Full Text] [Related]
20. CRISPR-Cas9 Mediated Gene-Silencing of the Mutant Huntingtin Gene in an In Vitro Model of Huntington's Disease.
Kolli N; Lu M; Maiti P; Rossignol J; Dunbar GL
Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28368337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
